Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$49.53
pos +0.37
+0.75%
Today's Range: 49.49 - 50.41 | MRK Avg Daily Volume: 11,598,800
Last Update: 02/10/16 - 4:00 PM EST
Volume: 11,026,692
YTD Performance: -6.93%
Open: $49.51
Previous Close: $49.16
52 Week Range: $45.69 - $61.70
Oustanding Shares: 2,793,543,137
Market Cap: 136,408,711,380
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 8 8 7
Moderate Buy 0 0 0 0
Hold 7 6 6 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.08 1.86 1.86 2.00
Latest Dividend: 0.46
Latest Dividend Yield: 3.77%
Dividend Ex-Date: 12/11/15
Price Earnings Ratio: 13.60
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
13.60 31.20 26.96
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-9.37% -15.72% 19.38%
GROWTH 12 Mo 3 Yr CAGR
Revenue -4.10 -0.16 -0.06
Net Income -62.60 -0.29 -0.11
EPS -61.60 -0.22 -0.08
Earnings for MRK:
EBITDA 7.55B
Revenue 39.50B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.85 $0.90 $3.71 $3.78
Number of Analysts 6 4 7 10
High Estimate $0.90 $0.92 $3.80 $4.05
Low Estimate $0.82 $0.88 $3.61 $3.51
Prior Year $0.85 $0.86 $3.59 $3.71
Growth Rate (Year over Year) 0.39% 4.94% 3.34% 1.89%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
In a year's time, investors may look back and think this was a great entry point.
The year has not started the way most pundits and prognosticators had envisioned.
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
These biotech/pharma picks could give you a very happy new year.
Use an initial percentage stop above the 50-day moving average.
Health care names Merck and Baxter are troubling.
This year's group had no bite, but the hope is for a better showing from the 2016 Dogs.
History indicates pharmaceutical companies with low multiples offer payoffs down the road.

Columnist Conversations

Juniper appears headed for a re test of major support near its 2015 low. With today's 1.5% loss JNPR is ...
$550 million to buy.
Spooking the markets now.
SPY $185.75 IWM $96.24

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.